

**Anti-Complement component C3a/C3a (desArg) (human)
 Mouse monoclonal antibody**

Subclass: IgG1/k

PRODUCT NO.

GAU 013-16

Clone: K13/16-5.7

PRESENTATION

Preparation: Protein-A/G purified

Content: Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: 4-8°C without exposure to light. No precautions necessary during handling.

ANTIGEN

Complement C3a is an anaphylatoxin of 77 amino acid residues released by the action of the C3 convertases on the N-terminal of the alpha chain of C3. It is rapidly inactivated by serum carboxypeptidase N which removes the C-terminal arginine residue generating C3a (desArg).

IMMUNOGEN

Human C3a adsorbed onto aluminum hydroxide gel (1)

SPECIFICITY

GAU 013-16 is specific for human C3, C3a and C3a (desArg) (1) and does not cross-react with C4a or C5a (2, 3).

EPI TOPE SPECIFICITY

GAU 013-16 recognizes a different epitope on the 9 kDa C3a than GAU 017-01 (2, 3). No reaction is seen with a synthetic octapeptide representing the C3a C-terminal (2).

REACTIVITY

GAU 013-16 can be used as a capture antibody in sandwich ELISA with GAU 017-01 as a biotinylated detection antibody (4). GAU 013-16 can also be used to immunopurify C3a (5, 6). GAU 013-16 effectively inhibits the biological activity of C3a in a guinea-pig platelet activation assay (6).

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

IMMUNIZATION

Female BALB/c mice immunized by intraperitoneal injection

APPLICATION

Method	Usability	References
ELISA	Yes	1, 2, 6
Immunoblotting	Yes	2, 6
Immunohistochemistry	Not determined	

REFERENCES

1. Oppermann M, Haubitz M, Quintin E, Götze O (1988) Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and Factor B. *Klin Wochenschr* 66:857-864.
2. Nezlín R, Freywald A, Oppermann M (1993) Proteins separated from human IgG molecules. *Mol. Immunol.* 30:935-940.
3. Oppermann M, Liebmann F, Götze O. (1987) Purification and quantification of human C3a anaphylatoxin using monoclonal antibodies. *Complement* 4:205-206
4. Oppermann M, Kurts C, Zierz R, Quintin E, Weber MH, Gotze O (1991) Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. *Kidney Int.* 40:939-947.
5. Püschel GP, Hespeling U, Oppermann M, Dieter P (1993) Increase in prostanoid formation in rat liver macrophages (Kupffer cells) by human anaphylatoxin C3a. *Hepatology.* 18(6):1516-21.
6. Puschel GP, Oppermann M, Muschol W, Gotze O, Jungermann K. (1989) Increase of glucose and lactate output and decrease of flow by human anaphylatoxin C3a but not C5a in perfused rat liver. *FEBS Lett.* 16:243(1):83-7.

This product is not for further manufacture

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.